Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Zelnorm For Chronic Constipation Should Exclude Males And Seniors – Cmte.

Executive Summary

Novartis' Zelnorm should be approved for treatment of patients with chronic constipation who are under 65 years of age and female, FDA's Gastrointestinal Drugs Advisory Committee recommended July 14
Advertisement

Related Content

FDA Review Of Fertility Drug Use For Safety Signals To Use IMS Data
FDA Review Of Fertility Drug Use For Safety Signals To Use IMS Data
Novartis Plans Chronic Constipation Disease Ads Following Zelnorm Approval
Novartis To Assess Zelnorm “Medguide” Distribution In Phase IV Study
Novartis To Assess Zelnorm “Medguide” Distribution In Phase IV Study
Novartis Plans Chronic Constipation Disease Ads Following Zelnorm Approval
Novartis Revises Zelnorm Labeling With Diarrhea, Ischemic Colitis Risk Info
Novartis Revises Zelnorm Labeling With Diarrhea, Ischemic Colitis Risk Info

Topics

Advertisement
UsernamePublicRestriction

Register

PS044372

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel